The study adds to growing evidence around the utility of cell-free DNA testing in lung cancer patients, while highlighting shortcomings of the approach.
The Navify software, which Roche launched today, provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer.
My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The agriculture company said it will use the technology it has licensed for new applications in crop editing and for research to bring new foods to market.
Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers.
Breakthrough UV-C Performance Enables Better Control for Lab Managers
This white paper makes the case for why UV LED technology deserves serious consideration by RNA sequencing labs for controlling ribonuclease in a laboratory setting. It describes Phoseon’s findings related to LED light engines for the inactivation of RNases in a laboratory setting.
Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.
